LSA
FATE icon

L & S Advisors’s Fate Therapeutics FATE Stock Holding History

L & S Advisors’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,946
Closed -$559K – 249
2022
Q3 		$559K Buy
+24,946
New +$721K 0.1% 159
2022
Q1 		– Sell
-25,513
Closed -$1.49M – 295
2021
Q4 		$1.49M Buy
25,513
+8,414
+49% +$477K 0.16% 151
2021
Q3 		$1.01M Sell
17,099
-5,548
-24% -$435K 0.11% 193
2021
Q2 		$1.97M Buy
22,647
+503
+2% +$40.5K 0.21% 147
2021
Q1 		$1.83M Sell
22,144
-2,375
-10% -$228K 0.21% 155
2020
Q4 		$2.23M Sell
24,519
-2,602
-10% -$162K 0.26% 135
2020
Q3 		$1.08M Buy
27,121
+4,879
+22% +$170K 0.15% 186
2020
Q2 		$763K Buy
22,242
+4,012
+22% +$120K 0.11% 193
2020
Q1 		$405K Buy
+18,230
New +$461K 0.08% 186

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

L & S Advisors's FATE Position: Q4 2022 in Review

L & S Advisors sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 24,946 shares — an estimated $559K sold.

L & S Advisors first reported a position in FATE in Q1 2020 and held it in 9 quarters. The position peaked at $2.23M in Q4 2020. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • L & S Advisors reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • L & S Advisors sold 24,946 Fate Therapeutics shares in Q4 2022, an estimated $559K.
  • L & S Advisors first reported a position in Fate Therapeutics in Q1 2020 and held it in 9 quarters.
  • L & S Advisors's Fate Therapeutics position peaked at $2.23M in Q4 2020.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on L & S Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.